New Zealand at a glance
- Population
- 5.3 million 2025
- Life expectancy at birth
- 82.0 years, 2024
- People aged 65 and over
- 17.6 % of people, 2025
- Health spending per person
- 5,022 US$ per person, 2024
- Doctors
- 3.61 per 1,000 people, 2022
Updated
Reviewed by Chandani Patel
New Zealand ALS Treatment Market Industry Trends and Forecast to 2034: Segmented by (Drug, Route, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$8.4 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $9.2 Mn | — | — |
| 2025 (base) | $9.9 Mn | +$0.7 Mn | — |
| 2026 (forecast) | $10.6 Mn | +$0.7 Mn | +7.1% |
| 2027 (forecast) | $11.3 Mn | +$0.8 Mn | +14.7% |
| 2028 (forecast) | $12.1 Mn | +$0.8 Mn | +22.8% |
| 2029 (forecast) | $13.0 Mn | +$0.9 Mn | +31.6% |
| 2030 (forecast) | $13.9 Mn | +$0.9 Mn | +40.9% |
| 2031 (forecast) | $14.9 Mn | +$1.0 Mn | +50.9% |
| 2032 (forecast) | $15.9 Mn | +$1.1 Mn | +61.6% |
| 2033 (forecast) | $17.1 Mn | +$1.1 Mn | +73.1% |
| 2034 (forecast) | $18.3 Mn | +$1.2 Mn | +85.4% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $9.9 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $18.3 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 7.1% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Also called | Amyotrophic Lateral Sclerosis (ALS) Treatment |
| Segments | Drug, route and end user (see all) |
| Key players | Biogen Inc, Mitsubishi Tanabe Pharma Corporation, Amylyx Pharmaceuticals, Sanofi, Cytokinetics (see all) |
| Regulator in New Zealand | MedsafeSource: Medsafe. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
ALS treatments aim to slow amyotrophic lateral sclerosis, a disease that destroys nerve cells controlling muscles.
Key segments of the ALS Treatment market include drug (Riluzole, Edaravone and Tofersen) and route (Oral, Intravenous and Intrathecal).
An ageing population, more people living with brain and nerve diseases, better diagnosis and the first disease-modifying treatments are driving the ALS Treatment market.
Biomarker-guided treatment, earlier diagnosis and new device-based therapies give the ALS Treatment market strong room to grow.
Hard-to-reach brain targets, high failure rates in trials, side effects and high prices for new therapies hold back the ALS Treatment market.
The ALS Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medsafe, part of the Ministry of Health, approves medicines before they can be sold.[1] Pharmac decides which medicines and medical devices the public health system pays for.[2]
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for ALS Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in New Zealand.
What doctors and scientists are doing in ALS Treatment right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 20 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 21 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 21 Nov 2026.
From our blog
New Zealand · 3 shared keywords
New Zealand · 2 shared keywords
New Zealand · 2 shared keywords
New Zealand · 2 shared keywords
New Zealand · 2 shared keywords
New Zealand · 2 shared keywords
Medical Devices · New Zealand
Healthcare Services · New Zealand
Healthcare Services · New Zealand
Digital Health · New Zealand
Digital Health · New Zealand
Medical Devices · New Zealand